Abstract: Strontium-89 (Sr-89) alone or with concurrent chemotherapy has a role in the treatment of patients with prostate cancer (PCP). The schedules for repeated doses of Sr-89 or for concurrent chemotherapy is undetermined. The objective of this study was to measure the effective half-life (Te) of Sr-89 using a detector available in a nuclear research facility. Blood and urine samples obtained from PCP treated with Sr-89 (Metastron, Amersham, U.K.) were measured for radioactivity with a High Pure Germanium (HPGe) detector in a gamma spectrometry system (Eurisys, France). Twenty-five urine and 22 blood samples were obtained from 8 patients during a period of 160 days after Metastron injection. Sr-89 radioactivity levels in blood and urine were quite low (Ͻ8.2 ϫ 10 -3 Ci/mL) in all patients after 21 days, whereas Sr-85 (available in 0.5% of Metastron) urine and, to a lesser extent, blood radioactivity levels were moderately high and could be detected up to 160 days. Based on Sr-85 urine levels, the calculated Sr-89 Te ranged from 9.6 to 20.7 days. Sr-89 Te can be routinely calculated in PCP based on HPGe detection of Sr-85 radioactivity levels in urine. This measurement can establish schedules for either repeated doses of Sr-89 or concurrent chemotherapy.
S
r-89 has a palliative effect in the treatment of hormoneresistant patients with prostate cancer (PCP) with bony metastases. 1 Several phase II studies reported on its having a therapeutic advantage when it was given with concurrent chemotherapy. 2, 3 Moreover, in a randomized study, Tue et al. 4 reported a longer overall survival over PCP treated with chemotherapy alone. The time during which the chemotherapy was delivered ranged from 6 weeks to 3 months, 4, 5 and repeated doses of Sr-89 were administered over 3 to 6 months. 6, 7 This timeframe depends on the biologic half-life (Tb) of Sr-89. In normal bone, the half-life is approximately 14 days, whereas it measures Ͼ50 days in reactive bone around metastasis. 8 At 90 days, the retention of Sr-89 ranged from a high of 88% (with significant metastatic involvement) to a low of 11% (with minimal involvement). 8 The currently available methods for measuring Sr-89 retention are based on bremsstrahlung imaging 9, 10 and on the detection of Sr-85. [11] [12] [13] The bremsstrahlung scan has a good correlation with ordinary bone scan and does confirm Sr-89 deposition in the metastatic bones. It cannot, however, be used repeatedly to measure the time scale of Sr-89 clearance. A whole-body Sr-85 scan requires higher doses of Sr-85, which, in turn, has a detrimental effect on bone marrow as a result of Sr-85's pure gamma emission. Nevertheless, Giammarile et al.
14 used this Sr-85 isotope to treat PCP, although this approach did not gain wide clinical use. Bone-marrow suppression may occur 4 to 6 weeks after Sr-89 treatment, 15 after which repeated doses of Sr-89 might be considered. When Sr-89 is given concurrently with chemotherapy, however, it should be repeated with caution because the chemotherapy itself induces bone marrow suppression.
The wide range of Sr-89 retention (11-90% at 90 days) 8 in the body, the available but not generally used methods for Sr-89 detection, and the combination of this material with chemotherapy preclude the establishment of accurate scheduling of repeated doses of Sr-89 or for the duration of chemotherapy.
One of the currently available Sr-89 products for medical use is Metastron (Amersham, U.K.). Based on the manufacturer's specifications, Metastron has Ͻ0.5% impurity of Sr-85. Sr-89, which is mainly a beta emitter, produces 909 KeV gamma rays at a very low yield, whereas Sr-85 produces gamma rays at an energy level of 514 KeV. Detection of such low doses of both Sr-89 and Sr-85 gamma emission is usually restricted to a well-equipped nuclear research facility.
The objective of this study is to measure the blood and urine levels of both Sr-89 and Sr-85 that are available in Metastron using a rather inexpensive device available in a nuclear research facility. We assume that by detecting Sr-89 and Sr-85 either in blood or urine, we will be able to accurately calculate the effective half-life (Te) of Sr-89 and, therefore, establish time schedules by which concurrent chemotherapy or repeated doses of Sr-89 can be given to responding patients.
MATERIALS AND METHODS
Patients who had hormone-resistant prostate cancer were enrolled in this study. They all had symptomatic bony metastases in at least 3 anatomic sites (including the head, rib cage, spine, pelvis, and others, based on bone scan uptake Ϯ computed axial tomography scan findings Ϯ plain bone films) requiring narcotics, as well as rising levels of prostatespecific antigen (PSA). The expected survival of all patients was at least 3 months. Blood and urine samples were obtained during a regular follow up after Sr-89 injection. The urine samples were obtained through a 24-hour urine collection.
Informed consent to participate was obtained from all patients, and this study was approved by the local ethics committee.
The injectable Sr-89 was supplied by Amersham Company (U.K.). We confirmed the manufacturer's specifications that Metastron has an impurity of Ͻ0.5% Sr-85 by measuring the radioactivity of a few drops in empty bottles. The Sr-89 was supplied in a small bottle containing 4 mL of the radioactive material. The injected Metastron dose in all patients was 4 mCi.
Blood and urine samples were measured for radioactivity using an HPGe detector in a gamma spectrometry system (Eurisys, France). This device has a minimal detectable activity (MDA) of 3.35 ϫ 10 -4 Ci/mL (12 Bq/mL) for Sr-89 and 3.23 ϫ 10 -8 Ci/mL (1.2 Bq/mL) for Sr-85 (with a counting time of 50,000 seconds). The appropriate MDA had been determined according to the actual time counting.
The patients' blood and urine levels of both Sr-85 and Sr-89 were measured at different time points. These levels were used to determine the Te (taking into account the known physical half-life ͓Tp͔ of both Sr-89 and Sr-85). The Tb could be calculated once the Te was known. Sr-85 and Sr-89 share the same Tb. The correlation among Te, Tb, and Tp is presented in the following equation:
RESULTS
Eight patients were enrolled to this study and their characteristics are presented in Table 1 . A total of 25 urine and 22 blood samples were obtained from 8 and 7 patients, respectively, during a period of 160 days after Metastron injection. Four out of 8 patients were treated with concurrent gemcitabine in an ongoing phase I-II study.
Blood Studies
Sr-89 levels were less than 8.2 ϫ 10 -3 Ci/mL in all patients after day 21 (Table 2) . Sr-85 levels above 1.2 ϫ 10 -6 Ci/mL were detected in 3 patients after 21 days and above 1 ϫ 10 -7 in 2 patients after 70 days (Table 2) .
Urine Studies
Sr-89 level less than 8.2 ϫ 10 -3 Ci/mL were detected in all patients after 21 days (Table 3) . Sr-85 levels above 1 ϫ 10 -6 Ci/mL were detected in all patients after 21 days and in 2 patients after 70 days (Table 3 ). A level above 1 ϫ 10 -7
Ci/mL was detected in 1 patient after 148 days (Table 3) .
Because the detection of urine Sr-85 level was possible over a prolonged period of time, we used this isotope to calculate the Tb (Table 4 ). The Sr-89 Te could be calculated based on the Tb value ( Table 4 ). The Sr-89 Te ranged from 9.6 to 20.7 days.
Three and 2 patients experienced a decrease in platelet (PLT) and white blood cell (WBC) counts, respectively. These patients were among the 4 patients who were exposed to chemotherapy (Table 1) . None of the nonexposed 4 patients developed bone marrow toxicity at the 6-week interval (Table 1) .
DISCUSSION
Sr-89 has a palliative role in the treatment of bone metastases. Robinson et al 16 reported 137 patients treated with 1.11-1.48 Mbq/kg Sr-89 of whom 80% were improved. Other studies reported similar results, 7, 10 whether it was given once or in repeated doses. The benefit was attributed to the radioactive isotope rather than to the stable strontium. 17 A better response rate was observed in patients with high performance status, 18 even if the painful lesions were exposed to previous radiotherapy. 19 Encouraging results were reported in using both chemotherapy and Sr-89. 20, 21 The scheduling of either repeated doses of Sr-89 or for the duration of chemotherapy was 3 to 6 months and 6 weeks to 3 months, respectively, and it was partly based on the assumption of Sr-89 Te. The ways Sr-89 Te was determined were based on either bremsstrahlung scans or by using Sr-85. Both ways have inherent faults and cannot be routinely done in PCP.
In this study, we were able to monitor blood and urine levels of both Sr-89 and Sr-85 in a relatively convenient and accurate way. We found that Sr-85, available in Metastron in a very low dose, produced gamma emission that could not only be highly detected by an HPGe detector but even better than the corresponding Sr-89 gamma emission. We could then calculate the Sr-85 Tb and, subsequently, the Sr-89 Te: 5 times the Te is the time interval that may leave 5% of Sr-89 in the body and this time interval probably serves to fix the timing for chemotherapy delivery or for repeated doses of Sr-89. The time it takes for bone marrow depression, which may occur 4 to 6 weeks after Sr-89 treatment, is another way for scheduling retreatment. This timeframe is not recommended, however, when Sr-89 is combined with chemotherapy because the chemotherapy itself may induce bone marrow toxicity. In our current study, 3 of 4 patients who were exposed to chemotherapy did develop bone marrow toxicity at 6 weeks after Sr-89 treatment, but none of the nonchemotherapy-treated patients did so (Table 1 ).
We also found that there is a wide difference in the Te between patients. This supports our policy that the schedule for treatment is better based on individual Sr-89 kinetics rather than being fixed at 6 weeks to 3 months (for concurrent chemotherapy) or 3 to 6 months (for repeated Sr-89 treatment). The device used for this study, an HPGE detector, is a basic inexpensive one that is available in an ordinary nuclear facility research unit. It might be modified for better clinical suitability and for a wider range of clinical indications (such as monitoring radiolabeled monoclonal antibody levels).
In conclusion, Sr-89 Te can be individually calculated based on Sr-85 urine levels measured by an HPGe detector. The individually calculated Te can then determine the schedule for repeated Sr-89 doses and for the duration of chemotherapy delivery. 
